Doctor Nathan Absalom

Journal Articles

• Absalom, N., El-Kamand, S., Chua, H. and Ahring, P. (2024), '[In Press] Follow the allosteric transitions to predict variant pathogenicity : a channel-specific approach', Brain, .
• Lin, S., Ahring, P., Keramidas, A., Liao, V., Moller, R., Chebib, M. and Absalom, N. (2023), '[In Press] Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity', Brain, .
• Absalom, N., Lin, S., Liao, V., Chua, H., Moller, R., Chebib, M. and Ahring, P. (2023), '[In Press] GABAA receptors in epilepsy : elucidating phenotypic divergence through functional analysis of genetic variants', Journal of Neurochemistry, .
• Absalom, N., Liao, V., Johannesen, K., Gardella, E., Jacobs, J., Lesca, G., Gokce-Samar, Z., Arzimanoglou, A., Zeidler, S., Striano, P., Meyer, P., Benkel-Herrenbrueck, I., Mero, I., Rummel, J., Chebib, M., M?ller, R. and Ahring, P. (2022), 'Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies', Nature Communications, vol 13, no 1 .
• Ahring, P., Liao, V., Lin, S., Absalom, N., Chebib, M. and Moller, R. (2022), 'The de novo GABRA4 p.Thr300Ile variant found in a patient with early-onset intractable epilepsy and neurodevelopmental abnormalities displays gain-of-function traits', Epilepsia, vol 63, no 9 , pp 2439 - 2441.
• Devenish, S., Winters, B., Anderson, L., Arnold, J., McGregor, I., Vaughan, C., Chebib, M. and Absalom, N. (2021), 'The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations', Neuropharmacology, vol 182 .
• Anderson, L., Heblinski, M., Absalom, N., Hawkins, N., Bowen, M., Benson, M., Zhang, F., Bahceci, D., Dohan, P., Chebib, M., McGregor, I., Kearney, J. and Arnold, J. (2021), 'Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy', British Journal of Pharmacology, vol 178, no 24 , pp 4826 - 4841.
• Chow, C., Absalom, N., Biggs, K., King, G. and Ma, L. (2020), 'Venom-derived modulators of epilepsy-related ion channels', Biochemical Pharmacology, vol 181 .
• Absalom, N., Liao, V., Kothur, K., Indurthi, D., Bennetts, B., Troedson, C., Mohammad, S., Gupta, S., McGregor, I., Bowen, M., Lederer, D., Mary, S., De Waele, L., Jansen, K., Gill, D., Kurian, M., McTague, A., Moller, R., Ahring, P., Dale, R. and Chebib, M. (2020), 'Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies', Brain Communications, vol 2, no 2 .
• Qudah, T., Quek, G., Indurthi, D., Karim, N., Halliday, J., Absalom, N., McLeod, M. and Chebib, M. (2020), 'AE succinimide, an analogue of Methyllycaconitine, when bound generates a nonconducting conformation of the a4?2 nicotinic acetylcholine receptor', ACS Chemical Neuroscience, vol 11, no 3 , pp 344 - 355.
• Absalom, N., Liao, V. and Chebib, M. (2020), 'Ligand-gated ion channels in genetic disorders and the question of efficacy', International Journal of Biochemistry and Cell Biology, vol 126 .
• Absalom, N., Ahring, P., Liao, V., Balle, T., Jiang, T., Anderson, L., Arnold, J., McGregor, I., Bowen, M. and Chebib, M. (2019), 'Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic', Journal of Biological Chemistry, vol 294, no 15 , pp 6157 - 6171.
• Anderson, L., Absalom, N., Abelev, S., Low, I., Doohan, P., Martin, L., Chebib, M., McGregor, I. and Arnold, J. (2019), 'Coadministered cannabidiol and clobazam : preclinical evidence for both pharmacodynamic and pharmacokinetic interactions', Epilepsia, vol 60, no 11 , pp 2224 - 2234.
• Indurthi, D., Qudah, T., Liao, V., Ahring, P., Lewis, T., Balle, T., Chebib, M. and Absalom, N. (2019), 'Revisiting autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutations in the nicotinic acetylcholine receptor reveal an increase in efficacy regardless of stochiometry', Pharmacological Research, vol 139 , pp 215 - 227.
• Naffaa, M., Absalom, N., Solomon, V., Chebib, M., Hibbs, D. and Hanrahan, J. (2016), 'Investigating the role of loop c hydrophilic residue 'T244' in the binding site of p1 GABAC receptors via site mutation and partial agonism', PLoS One, vol 11, no 5 .
• Hartiadi, L., Ahring, P., Chebib, M. and Absalom, N. (2016), 'High and low GABA sensitivity a4?2d GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries', Biochemical Pharmacology, vol 103 , pp 98 - 108.
• Che Has, A., Absalom, N., Van Nieuwenhuijzen, P., Clarkson, A., Ahring, P. and Chebib, M. (2016), 'Zolpidem is a potent stoichiometry-selective modulator of a1?3 GABAA receptors : evidence of a novel benzodiazepine site in the a1-a1 interface', Scientific Reports, vol 6 .
• Indurthi, D., Lewis, T., Ahring, P., Balle, T., Chebib, M. and Absalom, N. (2016), 'Ligand binding at the a4-a4 agonist-binding site of the a4?2 nAChR triggers receptor activation through a pre-activated conformational state', PLoS One, vol 11, no 8 .
• Lee, H., Absalom, N., Hanrahan, J., Van Nieuwenhuijzen, P., Ahring, P. and Chebib, M. (2016), 'A pharmacological characterization of GABA, THIP and DS2 at binary a4?3 and ?38 receptors : GABA activates ?38 receptors via the ?3(+)8(-) interface', Brain Research, vol 1644 , pp 222 - 230.
• Ahring, P., Bang, L., Jensen, M., Strobaek, D., Hartiadi, L., Chebib, M. and Absalom, N. (2016), 'A pharmacological assessment of agonists and modulators at a4[beta]2y2 and a4[beta]28 GABAA receptors : the challenge in comparing apples with oranges', Pharmacological Research, vol 111 , pp 563 - 576.
• Chua, H., Christensen, E., Hoestgaard-Jensen, K., Hartiadi, L., Ramzan, I., Jensen, A., Absalom, N. and Chebib, M. (2016), 'Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors : functional characteristics and molecular mechanism', PLoS One, vol 11, no 6 .